Global regulators should prioritize fix to pharma's fraud habit

07/30/2013 | Forbes

The integrity of the pharmaceutical industry has been put into question with China's probe into GlaxoSmithKline's marketing practices. Finding a solution to Big Pharma's fraud habit should be a top priority of regulators worldwide, Erika Kelton writes.

View Full Article in:


Published in Brief: